Conditions: Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 99
Healthy volunteers: yes

Brief summary:
The purpose of this study is to evaluate how safe LY2969822 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. This is the first time that this study drug is being given to participants. This study is for research purposes only and is not intended to treat any medical condition.

Detailed description:
Participants in Part A will complete three study periods, which together will last about 40 days. Participants in Parts B and C will complete one study period which will last about 17 days, but the total study time is about 40 days. Each participant may only enroll in one part. Screening is required within 28 days prior to the start of the study for all participants.

Arms:
arm 1: Single dose of LY2969822 administered orally in 2 of 3 study periods. arm 2: Single dose of placebo administered orally in 1 of 3 study periods. arm 3: LY2969822 administered orally for 14 days. arm 4: Placebo administered orally for 14 days. arm 5: LY2969822 administered orally for 14 days. arm 6: Placebo administered orally for 14 days.

Interventions: intervention 1: LY2969822 intervention 2: Placebo
Intervention descriptions: intervention 1: Capsules administered orally intervention 2: Capsules administered orally

Protocol document: